M&A and IPO Market Boom: MGM, Criteo Acquisition Talks and Holtec, Apnimed IPO Rush

M&A/IPO | Sat Jul 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) | 7 sources

Major acquisition negotiations involving MGM Resorts, Criteo, and Crinetics unfolded alongside IPO filings from Holtec and Apnimed, with follow-up developments on SpaceX's public listing.

Analysis

[MGM Resorts] entered acquisition talks with Barry Diller's People Inc. ^[1]

Diller proposed acquiring the shares he does not already own
Reported by Wall Street Journal

[Vertex Pharmaceuticals] acquired Crinetics Pharmaceuticals for $10 billion in all-cash deal ^[5]

Acquisition price of $85 per share sent stock surging 98%
Net acquisition value of $8.8 billion
Secured acromegaly treatment Palsonify
Aimed at diversifying rare disease pipeline

[Criteo] saw shares surge 20% on reported acquisition offer from Vista Equity Partners and Quinti Capital ^[4]

Offer carries over 50% premium to recent closing price
French adtech company
History of rejecting past acquisition offers
Under management review

[Holtec Nuclear] filed for U.S. IPO ^[2]

Nuclear energy services company
Expected to benefit from rising data center power demand
Joins nuclear sector IPO rush

[Apnimed] filed for IPO to fund commercialization of sleep apnea treatment ^[3]

Biotech backed by Shionogi
Developing oral treatment for obstructive sleep apnea
Near commercialization stage

[SpaceX] received $800 price target following historic IPO ^[6]^[7]

Began trading at $150 per share on June 12
IPO priced at $135
raising a total of $85.7 billion
Street-High price target of $800

M&A and IPO Market Boom: MGM, Criteo Acquisition Talks and Holtec, Apnimed IPO Rush

Analysis

Sources